{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-121856","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.855413+00:00","generated_at":"2026-05-30T04:46:10.953696+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Surrozen reports Q3 net loss of $1.4M (vs $10.4M YoY); gets $10M BI milestone for SZN-413","bullets":["Net loss narrowed to $1.4M from $10.4M in Q3 2023; collaboration revenue $10.0M (BI milestone).","Cash $31.0M at Sep 30, 2024; plus $10M milestone received Oct 2024 from Boehringer Ingelheim.","Phase 1b SZN-043 in severe alcohol-associated hepatitis: cohort 1 completed; no SAEs, reduced bilirubin/MELD; PoC data expected H1 2025.","Nominated wholly-owned preclinical ophthalmology candidates SZN-8141/8143/113 targeting Fzd4; SZN-413 advancing with BI.","New TCGFB research collaboration for TGF-β antibodies in IPF; up to $6M plus equity warrant of 3.38M shares."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-121856","json":"https://secwatch.observer/filing/0000950170-24-121856.json","markdown":"https://secwatch.observer/filing/0000950170-24-121856.md","text":"https://secwatch.observer/filing/0000950170-24-121856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000095017024121856/0000950170-24-121856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000095017024121856/srzn-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:46:10.953696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}